Gilde Healthcare establishes world-leading Impact Council
Seasoned experts from world-renowned institutes join Gilde Healthcare in its mission to invest in companies that provide better care at lower cost
Gilde Healthcare company Big Health builds out its Leadership Team with the appointment of five key Executives
Big Health, creators of the leading digital treatments for mental health, has appointed five executives to its senior leadership team as the company enters the next phase in the growth of its business. This follows the company's CEO transition in August 2022 to Arun Gupta, who was previously on the Big Health Board and continues to serve as Executive Chairman, and the appointment...
12 januari 2023
Gilde Healthcare company Volta medical secures €36M in Series B funding
test
Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced €36 million in new Series B funding, bringing the total capital raised to over €70 million. The funding round was led by U.S.-based Vensana Capital with co-investment […]
Gilde Healthcare company Adcendo Aps Announces License Agreement with Duality Biologics on Next-generation ADC Platform
test
Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, today announced a […]
Gilde Healthcare company LAVA Therapeutics announces exclusive worldwide license agreement with Seagen to advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager
Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced an exclusive license agreement in which Seagen...
Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study
Implantable shock absorber demonstrates clinically meaningful pain relief and functional improvement in data presented at OSET
Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022
Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry. Amphista is a world leading...
Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation
Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s successful Ev-AIFib Study. The Proof-of-Concept-Study investigated the use of Volta’s lead product...
Gilde Healthcare neemt Sanquin Reagents over
Investeert in schaalvergroting en ontwikkeling nieuwe medische tests
Loading...
These were all messages
f796b7e0cb